Close

Anti-CD4 TCR-ABR-β (XW-161) CAR Vector (XS-1122-YF2001)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-CD4 TCR-fused Antigen Binding Receptor (TCR-ABR) CAR is constructed for the engineering of T cells to target Human CD4. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv (XW-161) of anti-CD4 antibody linked to TCRβ subunit. The vector product was designed for the discovery and development of cellular therapy against Acute myeloid leukemia (AML). The TCR-ABR can effectively reprogram an intact TCR complex to recognize tumor surface antigens. TCR-ABR-T cells are shown to engage the signaling capacity of the entire TCR complex in an HLA-independent manner.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • CD4
  • Targeting Cell Type
  • T Cell
  • Targeting Diseases
  • Acute myeloid leukemia (AML)
  • Vector Name
  • pCDCAR1
  • Vector Length
  • ~8kb
  • Vector Type
  • Lentiviral vector
  • Receptor Construction
  • scFv-TCRβ
  • Discription of Signaling Cassetes
  • The scFv used to generate CAR-T cells or single domain antibodies can be fused to the extracellular N-termini of TCRα, TCRβ, CD3γ, CD3δ, or CD3ε subunits, resulting in the activation of target-specific TCR-ABR-T cells. TCR-ABR-T cells have been shown to use the entire TCR complex's signaling capacity in an HLA-independent manner.

Target

  • Clone
  • XW-161
  • Host
  • Mouse
  • Target Species
  • Human
  • Gene Name
  • CD40
  • Synonyms
  • CD40; p50; Bp50; CDW40; TNFRSF5
  • Introduction
  • This gene encodes the CD4 membrane glycoprotein of T lymphocytes. The CD4 antigen acts as a coreceptor with the T-cell receptor on the T lymphocyte to recognize antigens displayed by an antigen presenting cell in the context of class II MHC molecules. The CD4 antigen is also a primary receptor for entry of the human immunodeficiency virus through interactions with the HIV Env gp120 subunit. This gene is expressed not only in T lymphocytes, but also in B cells, macrophages, granulocytes, as well as in various regions of the brain. The protein functions to initiate or augment the early phase of T-cell activation, and may function as an important mediator of indirect neuronal damage in infectious and immune-mediated diseases of the central nervous system. Multiple alternatively spliced transcript variants encoding different isoforms have been identified in this gene.

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-CD4 TCR-ABR (scFv-TCRβ, XW-161) CAR Plasmid, pCDCAR1 (XS-1122-YF2001). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.